# Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC

- Link: https://www.thailand-business-news.com/pr-news/phrontline-biopharma-doses-first-patient-in-global-phase-i-ii-trial-of-tj102-an-fr%ce%b1-x-cdh6-bispecific-dual-payload-adc
- Published: 2026-09-30T20:53:00+07:00
- Author: PR Newswire

_First clinical program built on Phrontline’s DLP1 branched dual-payload linker 
platform_

HANGZHOU, China and SHANGHAI, Sept. 30, 2026 /PRNewswire/ — Phrontline Biopharma,
a clinical-stage biotechnology company developing next-generation antibody-drug 
conjugates (ADCs), today announced that the first patient has been dosed in its 
global, first-in-human Phase I/II study of TJ102, an investigational FRα (FOLR1)
× CDH6 bispecific dual-payload ADC, in patients with advanced or metastatic ovarian
cancer and other solid tumors. The study is being conducted under an IND cleared
by the U.S. FDA and a clinical trial application approved by China’s NMPA.

"Dosing the first patient with TJ102 is an important milestone for Phrontline," 
said Zhaoyuan "Tony" Chen, Ph.D., Chief Executive Officer of Phrontline Biopharma."
TJ102 combines dual tumor targeting with two mechanistically distinct, potency-balanced
payloads in a single, defined molecule. Our DLP1 platform attaches a pre-assembled
dual-payload linker to the antibody in one step, supporting scalable manufacturing
and consistent product quality."

The open-label, multicenter study (TJ102-I/II-001-G; NCT07778498) will assess safety,
tolerability, pharmacokinetics, immunogenicity and preliminary antitumor activity,
with dose escalation followed by dose-optimization and expansion cohorts to select
recommended dose(s) for further development.

"This trial tests the central hypothesis behind TJ102: that targeting both FRα and
CDH6 while co-delivering two distinct payloads may overcome the antigen heterogeneity
and resistance that limit single-target, single-payload ADCs," said Martín Sebastian
Olivo, MD, MSc, Chief Medical Officer of Phrontline Biopharma. "Our immediate priority
is to rigorously characterize safety, pharmacokinetics and early signs of clinical
activity."

**About TJ102**

TJ102 is an investigational IgG1 bispecific ADC targeting FRα and CDH6, two antigens
expressed in ovarian and other solid tumors. Its DLP1 linker-payload is a branched,
protease-cleavable linker carrying a topoisomerase I inhibitor and a potency-balanced
microtubule inhibitor. Four DLP1 units are conjugated to each antibody in a single
step, yielding a defined 4 + 4 payload composition (drug-to-antibody ratio of 8).
TJ102 has not been approved by any regulatory authority, and its safety and efficacy
have not been established.

**About Phrontline Biopharma**

Phrontline Biopharma is a clinical-stage biotechnology company headquartered in 
Hangzhou, China, developing next-generation antibody-drug conjugates (ADCs) for 
solid tumors. The company combines bispecific antibody engineering with a proprietary
toolbox of payloads spanning multiple mechanisms of action, including topoisomerase
I, microtubule, NMT, ATR and pan-RAS inhibitors, and a branched dual-payload linker
platform that pairs complementary payloads in a single, defined molecule. Phrontline’s
pipeline of bispecific and dual-payload ADCs is designed to address tumor heterogeneity,
treatment resistance and unmet medical need. For more information, visit [www.phrontlinebio.com](https://www.phrontlinebio.com/).

**Forward-Looking Statements**

This press release contains forward-looking statements, including statements regarding
the clinical development, potential benefits and manufacturability of TJ102 and 
the DLP1 platform. These statements are based on current expectations and are subject
to risks and uncertainties, including those inherent in drug development, that could
cause actual results to differ materially. Phrontline undertakes no obligation to
update any forward-looking statement except as required by law.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Phrontline Biopharma Doses First Patient in Global Phase I/II Trial of TJ102, an FRα × CDH6 Bispecific Dual-Payload ADC ](http://www.prnasia.com/story/archive/5060435_CN60435_0?rand=184833)
